Mehmet A. Bilen
Experienced in Neuroendocrine Tumor

Dr. Mehmet A. Bilen

Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
17 Years of Experience
Experienced in Neuroendocrine Tumor
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mehmet Bilen is an Oncologist in Atlanta, Georgia. Dr. Bilen has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 245 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Neuroendocrine Tumor.

Graduate Institution
Hacettepe University Faculty Of Medicine, 2008
Residency
Baylor College of Medicine
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2016
Fellowships
UT MD Anderson Cancer Center
Hospital Affiliations
Emory University Hospital Midtown
Emory Johns Creek Hospital
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Turkish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunshine Health
  • EPO
  • HMO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: ARX517 Anti-PSMA AS269-Conjugated Monoclonal Antibody
Study Phase: Phase 1
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination with Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer
A Phase I/Ib Open Label, Single-Arm Study of Cabozantinib in Combination with Enfortumab Vedotin (EV) in the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: March 06, 2025
Intervention Type: Other, Drug
Study Drugs: Cabozantinib S-malate, Enfortumab Vedotin
Study Phase: Phase 1
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Tremelimumab
Study Phase: Phase 2
View 7 Less Clinical Trials

245 Total Publications

Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes.
Journal: Prostate cancer and prostatic diseases
Published: August 12, 2025
Similar Doctors
Elite in Neuroendocrine Tumor
Dr. Walid L. Shaib
Hematology Oncology | Hematology | Oncology
Elite in Neuroendocrine Tumor
Dr. Walid L. Shaib
Hematology Oncology | Hematology | Oncology

Wellstar Medical Group LLC

677 Church St Ne, Suite 100p, 
Marietta, GA 
 (18.0 miles away)
470-793-8585
Languages Spoken:
English, Arabic, French, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Walid Shaib is a Hematologist Oncology specialist and a Hematologist in Marietta, Georgia. Dr. Shaib is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shaib is currently accepting new patients.

Olatunji B. Alese
Distinguished in Neuroendocrine Tumor
Dr. Olatunji B. Alese
Oncology
Distinguished in Neuroendocrine Tumor
Dr. Olatunji B. Alese
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
25+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Olatunji Alese is an Oncologist in Atlanta, Georgia. Dr. Alese has been practicing medicine for over 25 years and is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Liver Embolization.

Distinguished in Neuroendocrine Tumor
Dr. Eyal Meiri
Oncology
Distinguished in Neuroendocrine Tumor
Dr. Eyal Meiri
Oncology

Piedmont Providers LLC

1968 Peachtree Nw Rd, 
Atlanta, GA 
 (4.4 miles away)
404-605-5000
Languages Spoken:
English, Hebrew, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Eyal Meiri is an Oncologist in Atlanta, Georgia. Dr. Meiri is rated as a Distinguished provider by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer. Dr. Meiri is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bilen's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 10 Advanced Conditions
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile